Business Leader Cancer Research

Tempus Founder Eric Lefkofsky says Increased Funding Opens New Horizons

Tempus, a company founded in 2015 by Eric Lefkofsky, aims to bring Artificial Intelligence (AI) technology to doctors and researchers to increase the effectiveness of precision medicine. The company helps medical professionals make real-time decisions about diagnosis and treatment by relying on technology and data mined from a patient’s genetic information. Though it initially focused on supporting physicians treating cancer, Eric Lefkofsky explains, Tempus has since branched out – not only in terms of professionals with whom it partners.

 

The company now also works directly with researchers), but also with regard to the medical issues it targets. Since its founding, Tempus has expanded into the fields of mental health, cardiology, and infectious diseases, and has been active in the fight against COVID-19 (LATimes). 

All of this has been made possible, according to Eric Lefkofsky, by a steady influx of funding and earnings. Though 2020 was a difficult year for many in the medical community, Tempus boasted its healthiest financial year yet, raising over one billion dollars in 2020 alone. As the company grows, Eric Lefkofsky has said he is ever-vigilant for new partnerships and ventures to help the medical community tackle some of its deadliest challenges. In fact, Tempus already has its next move in mind and hopes to branch out into the field of diabetes in the near future.